Repositorio Dspace

Listar02.06.01. Investigación y comunicación científica por tema "Capecitabine/therapeutic use/administration & dosage"

Listar02.06.01. Investigación y comunicación científica por tema "Capecitabine/therapeutic use/administration & dosage"

Ordenar por:Orden:Resultados:

  • FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial 
    Rojo, Federico; Taylor, Clive-R; Barrios, Carlos; Torrecillas, Laura; Ruiz-Borrego, Manuel; Pérez-Buira, Sandra; Bines, José; Guerrero-Zotano, Ángel; García-Saenz, José-A; Torres, Roberto; de-la-Haba-Rodríguez, Juan; Ayala-de-la-Peña, Francisco; Gómez, Henry; Llombart, Antonio; Rodríguez-de-la-Borbolla, María; Baena-Canada, José-Manuel; Barnadas, Agusti; Calvo, Lourdes; Herranz, Jesús; Rincon, Raúl; Caballero, Rosalía; Bermejo, Begoña; Ray, Partha-S; Martin, Miguel (AMER ASSOC CANCER RESEARCH, 2025-09-02)
    PURPOSE: In a prespecified GEICAM_CIBOMA trial (NCT00130533) correlative analysis, PAM50 non-basal-like breast cancer (non-BLBC) status distinguished patients with triple-negative breast cancer (TNBC) who are most likely ...
  • Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry 
    Arias-Martínez, Aranzazu; Martínez-de-Castro, Eva; Gallego, Javier; Arrazubi, Virginia; Custodio, Ana-Belén; Fernández-Montes, Ana; Díez, Marc; Hernández, Raquel; Limón-Mirón, María-Luisa; Cano, Juana-María; Vidal-Tocino, Rosario; Macías, Ismael; Visa, Laura; Martín-Richard, Marta; Sauri, Tamara; Hierro, Cinta; Gil, Mireia; Cerdá, Paula; Martínez-Moreno, Elia; Martínez-Lago, Nieves; Merida-García, Antonio-José; Gómez-González, Lucía; García-Navalón, Francisco-Javier; Ruiz-Martín, Maribel; Marín, Gema; López-López, Flora; Rupérez-Blanco, Ana-Belén; Fernández, Alejandro-Francisco; Jiménez-Fonseca, Paula; Carmona-Bayonas, Alberto; Álvarez-Mancenido, Felipe (Springer Int Publ Ag, 2024-07)
    BACKGROUND: The optimal chemotherapy backbone for HER2-negative advanced esophagogastric cancer, either in combination with targeted therapies or as a comparator in clinical trials, is uncertain. The subtle yet crucial ...

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta